Comprehensive analysis of transcriptomic biomarkers for predicting response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma

Comprehensive analysis of transcriptomic biomarkers for predicting response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma

Saved in:

Bibliographic Details
Main Authors:	Binghua Li, Jingyuan Wen, Zhu Xu, Peng Yan, Bing Han, Decai Yu
Format:	Article
Language:	English
Published:	Korean Association for the Study of the Liver 2025-01-01
Series:	Clinical and Molecular Hepatology
Subjects:	hepatocellular carcinoma immunotherapy atezolizumab plus bevacizumab biomarker immune checkpoint inhibitors
Online Access:	http://e-cmh.org/upload/pdf/cmh-2024-0628.pdf
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Safety and efficacy of atezolizumab/bevacizumab in unresectable hepatocellular carcinoma—a multicentric study
by: Merin Babu, et al.
Published: (2025-07-01)

Two cases of unresectable hepatocellular carcinoma treated via atezolizumab and bevacizumab combination therapy
by: Ryosuke Tsunemitsu, et al.
Published: (2023-06-01)

Second-line treatment patterns and outcomes in advanced HCC after progression on atezolizumab/bevacizumab
by: Meng Wu, et al.
Published: (2025-02-01)

Early bevacizumab dose and time modifications may affect efficacy of atezolizumab plus bevacizumab for advanced hepatocellular carcinoma treatment
by: F. Rossari, et al.
Published: (2025-06-01)

Serum FGF21 as a predictor of response to atezolizumab and bevacizumab in HCC
by: Risako Kohya, et al.
Published: (2025-05-01)

Atezolizumab plus bevacizumab in patients with unresectable or metastatic mucosal melanoma: 3‐year survival update and multi‐omics analysis
by: Jie Dai, et al.
Published: (2025-01-01)

Biomarker, efficacy and safety analysis of transcatheter arterial chemoembolization combined with atezolizumab and bevacizumab for unresectable hepatocellular carcinoma
by: Shaobo Zhang, et al.
Published: (2025-05-01)

Predictive biomarkers of survival in patients with advanced hepatocellular carcinoma receiving atezolizumab plus bevacizumab treatment
by: Young Eun Chon, et al.
Published: (2023-02-01)

Peripheral blood inflammatory score using a cytokine multiplex assay predicts clinical outcomes in patients treated with atezolizumab-bevacizumab for unresectable HCC
by: Hee Sun Cho, et al.
Published: (2025-06-01)

Atezolizumab and Bevacizumab in Therapy for Patients with Hepatocellular Carcinoma in Real Clinical Practice
by: G. A. Serebrennikov, et al.
Published: (2023-07-01)

Protocol of the IMPACT study: randomized, multicenter, phase 3 study evaluating the efficacy of immunotherapy (Atezolizumab) plus anti-VEGF therapy (Bevacizumab) in combination with transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma
by: Yoshihisa Kodama, et al.
Published: (2025-03-01)

Brain hemorrhage in patients with advanced hepatocellular carcinoma treated with atezolizumab and bevacizumab: two case reports
by: Bangju Kim, et al.
Published: (2025-06-01)

Lenvatinib versus sorafenib as second-line therapy following progression on atezolizumab–bevacizumab in patients with unresectable hepatocellular carcinoma: a multicenter retrospective study from Korea and Japan
by: Jaekyung Cheon, et al.
Published: (2025-01-01)

Atezolizumab plus bevacizumab and chemotherapy versus bevacizumab plus chemotherapy for metastatic cervical cancer: a cost-effectiveness analysis
by: Hongfu Cai, et al.
Published: (2024-10-01)

Improved survival with second-line hepatic arterial infusion chemotherapy after atezolizumab-bevacizumab failure in hepatocellular carcinoma
by: Ji Yeon Lee, et al.
Published: (2024-12-01)

Frontline evaluation: Atezolizumab–bevacizumab versus lenvatinib for BCLC stage B hepatocellular carcinoma exceeding the up‐to‐seven criteria
by: Masamichi Kimura, et al.
Published: (2024-09-01)

Retrospective Multicentre Real-Life Study Evaluating the Efficacy of Atezolizumab Combined with Bevacizumab for the Treatment of Metastatic Hepatocellular Carcinoma: HIREAL Study
by: Barbe-Richaud JB, et al.
Published: (2025-07-01)

Personalized approaches to the treatment of hepatocellular carcinoma using immune checkpoint inhibitors: Editorial on “Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial”
by: Naoshi Nishida
Published: (2025-01-01)

Transarterial therapy combined with bevacizumab plus immune checkpoint inhibitors as a neoadjuvant therapy for locally advanced HCC
by: Zhenyun Yang, et al.
Published: (2024-12-01)

Correspondence to letter to the editor on “Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial”
by: Sung Hwan Lee, et al.
Published: (2025-01-01)

Correspondence to editorial 1 on “Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: insights from the IMbrave150 Trial”
by: Sung Hwan Lee, et al.
Published: (2025-01-01)

Transcriptomic signature in advanced hepatocellular carcinoma tissue to predict combination immunotherapy response: Editorial on “Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial”
by: Hiroaki Kanzaki, et al.
Published: (2025-01-01)

Atezolizumab-Induced Ulcerative Colitis in Patient with Hepatocellular Carcinoma: Case Report and Literature Review
by: Hyuk Kim, et al.
Published: (2024-08-01)

Reply to correspondence on “Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial”
by: Hiroaki Kanzaki, et al.
Published: (2025-01-01)

Prior corticosteroid treatment alters cPBMC composition and IFNγ response to immunotherapy in canine cancer
by: Anna Barbara Emilia Zimmermann, et al.
Published: (2025-04-01)

Evaluation of Treatment Outcomes Using dNLR and GNRI in Combination Therapy With Atezolizumab and Bevacizumab for Hepatocellular Carcinoma
by: Atsushi Naganuma, et al.
Published: (2025-01-01)

Long-lasting remission in a metastatic hepatocellular carcinoma patient after combined regorafenib therapy and surgery
by: Elisabetta Goio, et al.
Published: (2020-09-01)

Anti‐Angiogenic Agents for Advanced Hepatocellular Carcinoma Induce Liver Atrophy
by: Taijiro Wake, et al.
Published: (2025-08-01)

Atezolizumab plus bevacizumab and chemotherapy as first-line therapy for cervical cancer: a cost-effectiveness analysis in the US
by: Yingtao Lin, et al.
Published: (2024-11-01)

Clinical characteristics, diagnosis, treatment, and prognosis of Atezolizumab-induced encephalitis, aseptic meningitis or meningoencephalitis
by: Qingzi Yan, et al.
Published: (2025-01-01)

Efficacy and safety of atezolizumab in the treatment of urothelial carcinoma: a systematic review and meta-analysis
by: Jun Xie, et al.
Published: (2025-04-01)

The prognostic value of systemic immune-inflammation index in patients with unresectable hepatocellular carcinoma treated with immune-based therapy
by: Tian He, et al.
Published: (2025-01-01)

Prognostic significance of combined PD-L1 expression in malignant and infiltrating cells in hepatocellular carcinoma treated with atezolizumab and bevacizumab
by: Jaejun Lee, et al.
Published: (2024-12-01)

Matching-adjusted indirect comparison of tislelizumab plus lenvatinib versus sintilimab plus bevacizumab biosimilar as first-line treatment for unresectable hepatocellular carcinoma
by: Kunyuan Wang, et al.
Published: (2025-06-01)

PD-1/PD-L1 blockade therapy with atezolizumab: a new paradigm in the treatment of non-small cell lung cancer (NSCLC)
by: Samaneh Moradi, et al.
Published: (2025-03-01)

Prolonged progression-free survival on epidermal growth factor receptor-tyrosine kinase inhibitors predicts superior response to atezolizumab-based therapy over chemotherapy in epidermal growth factor receptor-mutated non-small-cell lung cancer following progression
by: K. Morimoto, et al.
Published: (2025-06-01)

Efficacy and safety of neoadjuvant bevacizumab plus chemotherapy in locally advanced gastric cancer patients: a retrospective, comparative study
by: Bin Yin, et al.
Published: (2025-01-01)

Role of Immunotherapy in the Treatment of Hepatocellular Carcinoma
by: Irina Y. Dobrosotskaya, et al.
Published: (2025-04-01)

Advancing Adjuvant Immunotherapy in Hepatocellular Carcinoma: A Comprehensive Review
by: Akabane M, et al.
Published: (2025-06-01)

Adverse drug reactions to atezolizumab in combination with bevacizumab in hepatocellular carcinoma patients: an analysis of the food and drug administration adverse event reporting system database
by: Wanming He, et al.
Published: (2025-02-01)